$CLX

Clorox Just Raised Its Dividend Again. Can Earnings Keep Up?

Clorox (CLX) raised its annualized dividend to $5.00, marking a 5.86% yield. However, concerns arise due to an 85% payout ratio, 38% drop in operating cash flow, and increased liabilities from the GOJO acquisition. Management targets $5.70-$6.00 EPS in fiscal 2027, despite $200M+ inflation headwinds. The stock is down 33% over the past year.

Original reporting
Published Sep 28, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clorox Just Raised Its Dividend Again. Can Earnings Keep Up? — source image
Decision brief

The 30-second read

$CLXBearishLow
01

Why it matters

The thin coverage may lead to share price weakness, especially for income‑focused investors.

02

Market read

The article recaps known earnings data and focuses on dividend sustainability, offering limited new trading insight.

03

What to watch

Potential upside if GOJO acquisition turns accretive faster than expected.

Relevance 4/10Novelty 2/10Timing: none

Background

Clorox's latest dividend raise follows a recent earnings release that showed declining cash flow and higher leverage after the GOJO acquisition.

Company-level read

Ticker impact

$CLXBearishHigh confidence
Context

Clorox raised its annualized dividend to $5.00, citing an 85% payout ratio and a 38% drop in operating cash flow, raising coverage concerns.

Expected impact

likely downside as investors worry about dividend sustainability

Evidence & confidence

The article highlights thin dividend coverage and rising leverage, which are bearish signals for a dividend‑paying consumer staple.

Market effects

Raises concerns for other dividend‑heavy consumer staples with high payout ratios.

U.S. consumer‑staples sector may see modest pressure.

Limited to investors tracking dividend sustainability in the U.S. market.

Counterpoint

The dividend increase could attract yield‑seeking investors despite cash‑flow strain.

Key entities

  • Clorox

    U.S. consumer‑staples firm (ticker CLX).

  • GOJO Industries

    Acquired by Clorox, contributing to higher liabilities.

Related articles

$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

$CLXMed

The Clorox Company Q4 2026 Earnings Call Summary

Clorox held its Q4 2026 earnings call, citing value-seeking consumer behavior and inflation pressures. Management said most categories have recovered from a prior cyberattack, with Litter still lagging. It highlighted GOJO acquisition synergies, fiscal 2027 assumptions including Brent at $90/bbl, inflation over $200M, and free cash flow of 11% to 13% of sales.